Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5604213 | JANSSEN BIOTECH | 17-substituted steroids useful in cancer treatment |
Feb, 2014
(10 years ago) | |
US8822438 | JANSSEN BIOTECH | Methods and compositions for treating cancer |
Aug, 2027
(3 years from now) |
Zytiga is owned by Janssen Biotech.
Zytiga contains Abiraterone Acetate.
Zytiga has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Zytiga are:
Zytiga was authorised for market use on 28 April, 2011.
Zytiga is available in tablet;oral dosage forms.
Zytiga can be used as use in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer, use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.
Drug patent challenges can be filed against Zytiga from 29 April, 2015.
The generics of Zytiga are possible to be released after 24 August, 2027.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-765) | Feb 07, 2021 |
New Indication(I-663) | Dec 10, 2015 |
New Chemical Entity Exclusivity(NCE) | Apr 28, 2016 |
Drugs and Companies using ABIRATERONE ACETATE ingredient
NCE-1 date: 29 April, 2015
Market Authorisation Date: 28 April, 2011
Treatment: Use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel; Use in combination with...
Dosage: TABLET;ORAL